Patents by Inventor Emma L. Clark

Emma L. Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20220362379
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: March 28, 2022
    Publication date: November 17, 2022
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Jayantha Ratnayake, Graham A. Ross
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20210015919
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: August 13, 2020
    Publication date: January 21, 2021
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Graham A. Ross
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20200376120
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: August 17, 2020
    Publication date: December 3, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Graham A. Ross
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20200206348
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: February 20, 2020
    Publication date: July 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Jayantha Ratnayake, Graham A. Ross
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20190117769
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: September 6, 2018
    Publication date: April 25, 2019
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Lada Mitchell, Christina H. de Toledo Pelizon, Jayantha Ratnayake, Graham A. Ross
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20160175438
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; and treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag.
    Type: Application
    Filed: March 2, 2016
    Publication date: June 23, 2016
    Applicant: Genentech, Inc.
    Inventors: Sreedhara Alavattam, Lukas C. Amler, Mark C. Benyunes, Emma L. Clark, Christina H. de Toledo Pelizon, Zephania W. Kwong Glover, Lada Mitchell, Jayantha Ratnayake, Graham A. Ross, Ru-Amir Walker